Clinical Trials Logo

Filter by:
NCT ID: NCT03004248 Completed - Clinical trials for Glabellar Frown Lines

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

Start date: December 9, 2016
Phase: Phase 3
Study type: Interventional

This is a long term safety study of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines following single and repeat administration.

NCT ID: NCT03004131 Completed - Clinical trials for Seasonal Allergic Rhinitis

MP-AzeFlu Allergen Chamber - Onset of Action Study

Start date: January 7, 2017
Phase: Phase 4
Study type: Interventional

This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (MP-AzeFlu) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Chamber (EEC).

NCT ID: NCT03003533 Completed - Hemophilia A Clinical Trials

A Gene Transfer Study for Hemophilia A

Start date: January 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals with hemophilia A.

NCT ID: NCT03003247 Completed - Acne Vulgaris Clinical Trials

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Start date: November 2015
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

NCT ID: NCT03002194 Completed - Skin Abnormalities Clinical Trials

Change in Skin Elasticity With RF and PEMF

Start date: November 2016
Phase: N/A
Study type: Interventional

This study will measure the difference in skin elasticity in females only before and after treatment with radiofrequency and pulsed electromagnetic field therapy.

NCT ID: NCT03001895 Completed - Prostate Cancer Clinical Trials

Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer

Start date: July 1, 2017
Phase: Phase 2
Study type: Interventional

Prostate specific membrane antigen (PSMA) is a unique membrane bound glycoprotein, which is overexpressed manifold on prostate cancer cells and is well-characterized as an imaging biomarker of prostate cancer. Positron emission tomography / computer tomography (PET/CT) is a nuclear medicine procedure based on the measurement of positron emission from radiolabeled tracer molecules. 18F-DCFPyL is a tracer for prostate cancer PET imaging which binds to PSMA. The strength of functional imaging methods is in distinguishing tissues according to metabolism rather than structure. Studies have shown that PET/CT imaging with 18F-DCFPyL can detect prostate cancer lesions with excellent contrast and a high detection rate even when the level of prostate specific antigen is low. The objective of this study is to evaluate if the patient-wide SUVmax on 18F-DCFPyL PET/CT in locoregional and metastatic prostate cancer correlates with histopathologic Gleason score at initial biopsy. It is hypothesized that SUVmax will correlate positively with Gleason score. This is of interest because non-invasive risk stratification may be possible in the future.

NCT ID: NCT03001869 Completed - Prostate Cancer Clinical Trials

68Ga-PSMA PET/CT in Prostate Cancer

Start date: July 1, 2017
Phase: Phase 3
Study type: Interventional

The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and as a diagnostic and decision making tool in the management prostate cancer patients.The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA PET/CT vs CT on a per-patient and per-lesion basis.

NCT ID: NCT03001388 Completed - Clinical trials for Cystic Fibrosis Liver Disease

Longitudinal Assessment of Transient Elastography in Cystic Fibrosis

Start date: March 8, 2017
Phase:
Study type: Observational

To determine if transient elastography (TE), when combined with ultrasound (US) pattern characterization can improve the prediction of progression to a nodular pattern on US. To confirm the feasibility of obtaining TE measurements in children with Cystic Fibrosis (CF) To prospectively assess whether TE data are associated with conventional laboratory markers of hepatic fibrosis To determine the variability of TE measurements taken at different sites in the same patient

NCT ID: NCT03000699 Completed - Clinical trials for Substance Dependence

Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether computer bias modification for interpretation bias (CBM-I) is effective in the reduction of suicidal ideation in substance use disorders.

NCT ID: NCT03000439 Completed - Clinical trials for Arthritis Juvenile Idiopathic

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Start date: May 10, 2018
Phase: Phase 3
Study type: Interventional

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA flare. An interim analysis for efficacy and futility will be conducted when at least 20 flares have been observed. If either criterion is met, the study will be stopped. If neither criterion is met, the study will continue until the requisite number of flares are observed as determined by the number of flares included in the interim analysis and a statistical penalty for conducting the interim analysis.